REGENXBIO Inc. (RGNX) |
|
20.55 -0.37 (-1.77%)
|
03-22 12:40 |
|
Open: |
20.93 |
Pre. Close: |
20.92 |
|
High:
|
20.93 |
Low:
|
20.34 |
|
Volume:
|
82,086 |
Market Cap:
|
935(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 12:19:34 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 27.03 One year: 29.57 |
| Support: |
Support1: 19.62 Support2: 16.33 |
| Resistance: |
Resistance1: 23.14 Resistance2: 25.31 |
| Pivot: |
21.72  |
| Moving Average: |
MA(5): 20.71 MA(20): 21.85
MA(100): 22.53 MA(250): 25.12 |
| MACD: |
MACD(12,26): -0.6 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 21  %D(3): 17.7 |
| RSI: |
RSI(14): 42.1 |
| 52-week: |
High: 35.72 Low: 18.69 |
| Average Vol(K): |
3-Month: 397 (K) 10-Days: 441 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RGNX ] has closed above bottom band by 28.0%. Bollinger Bands are 59.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
21.4 - 21.48 |
21.48 - 21.57 |
|
Low:
|
20.34 - 20.44 |
20.44 - 20.53 |
|
Close:
|
20.77 - 20.92 |
20.92 - 21.06 |
|
Company Description |
|
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. |
Headline News |
Wed, 22 Mar 2023
Hennion & Walsh Asset Management Inc. Acquires 11394 Shares of ... - MarketBeat
Fri, 10 Mar 2023
Rockville biotech Shuttle Pharma inks deal to advance key drug ... - The Business Journals
Thu, 09 Mar 2023
Cubist Systematic Strategies LLC Has $894000 Holdings in ... - MarketBeat
Wed, 08 Mar 2023
REGENXBIO to Participate in Upcoming Investor Conferences - Regenxbio (NASDAQ:RGNX) - Benzinga
Sun, 05 Mar 2023
Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be - Simply Wall St
Sat, 04 Mar 2023
Q3 2023 Earnings Estimate for REGENXBIO Inc. (NASDAQ:RGNX ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
43 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
7.7 (%) |
|
% Held by Institutions
|
88.3 (%) |
|
Shares Short
|
3,060 (K) |
|
Shares Short P.Month
|
2,550 (K) |
Stock Financials |
|
EPS
|
-2.99 |
|
EPS Est Next Qtl
|
-0.77 |
|
EPS Est This Year
|
-2.94 |
|
EPS Est Next Year
|
-2.96 |
|
Book Value (p.s.)
|
10.07 |
|
Profit Margin (%)
|
15.3 |
|
Operating Margin (%)
|
24.5 |
|
Return on Assets (ttm)
|
8.7 |
|
Return on Equity (ttm)
|
14.3 |
|
Qtrly Rev. Growth
|
-13.9 |
|
Gross Profit (p.s.)
|
5.47 |
|
Sales Per Share
|
11.08 |
|
EBITDA (p.s.)
|
2.98 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
173 (M) |
|
Levered Free Cash Flow
|
100 (M) |
Stock Valuations |
|
PE Ratio
|
-6.91 |
|
PEG Ratio
|
-1.9 |
|
Price to Book value
|
2.04 |
|
Price to Sales
|
1.85 |
|
Price to Cash Flow
|
5.13 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
